Clinical Trials Logo
  1. Home
  2. Malaria, Falciparum
  3. NCT00529867

Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria

Malaria, Falciparum Clinical Trial

Official title:
A Randomized Open-Label Trial of the Efficacy of Artemether-Lumefantrine Suspension Compared With Artemether-Lumefantrine Tablets for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Less Than Five Years in Western Kenya

Clinical Trial Summary

The purpose of this study is to compare the safety and efficacy in children aged 6 - 59 months with uncomplicated malaria, treated with either conventional artemether/lumefantrine tablets(Coartem®) or artemether/ lumefantrine suspension (Co-artesiane®) in Western Kenya

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00529867
Study type Interventional
Source Dafra Pharma
Contact
Status Completed
Phase Phase 4
Start date May 2007
Completion date December 2007
View Details
See also
  Status Clinical Trial Phase
Completed NCT02329301 - Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia N/A
Recruiting NCT01944189 - Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics Phase 4
Completed NCT01325974 - Time to Become Negative of Three Rapid Diagnostic Tests for Malaria N/A
Terminated NCT01442168 - Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria Phase 1/Phase 2
Terminated NCT00374205 - Randomized Trial on Effectiveness of ACTs in Ghana Phase 4
Completed NCT00375128 - Sporozoite Challenge of Polyprotein Vaccinees Phase 1/Phase 2
Completed NCT04609098 - Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2) Phase 2
Completed NCT02851108 - Methylene Blue Against Falciparum Malaria in Burkina Faso Phase 2
Terminated NCT02281344 - MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants Phase 1
Completed NCT02434952 - Safety and Tolerability of Low Dose Primaquine Phase 4
Completed NCT01213966 - Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection Phase 2
Completed NCT00479206 - Artemisinin Resistance in Cambodia N/A
Completed NCT00126906 - Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi N/A
Completed NCT01019408 - Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan Phase 4
Completed NCT00137553 - The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children Phase 4
Completed NCT02637128 - In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria Phase 4
Completed NCT01222962 - Food Interaction Study on the Pharmacokinetics of Eurartesim™ (DHA and PQP)in Healthy Male Adult Volunteers Phase 1
Unknown status NCT00152204 - The Community Effectiveness of IPTi in Southern Tanzania Phase 3
Terminated NCT00084240 - Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia Phase 2/Phase 3
Completed NCT00137514 - Chloroquine and Amodiaquine for Treatment of Malaria in Children Phase 4